- Home
- CLCO vs ASMB Comparison
CLCO vs ASMB Comparison
Compare CLCO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLCO | ASMB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.5M | 553.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | CLCO | ASMB |
|---|---|---|
| Price | $9.79 | $31.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | ★ 247.9K | 144.5K |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $327,762,000.00 | $37,191,000.00 |
| Revenue This Year | $4.24 | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.86 | ★ N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $4.51 | $7.75 |
| 52 Week High | $10.00 | $39.71 |
Technical Indicators
Market Signals| Indicator | CLCO | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 41.99 |
| Support Level | $9.80 | $31.51 |
| Resistance Level | $10.00 | $33.97 |
| Average True Range (ATR) | 0.06 | 2.02 |
| MACD | -0.01 | -0.37 |
| Stochastic Oscillator | 20.37 | 6.28 |
Price Performance
Historical ComparisonAbout CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.